Steven Cohen’s Atea Pharmaceuticals AVIR Stock Holding History

Steven Cohen’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-119,553	Closed	-$643K	–	4002
2026 Q1	$643K	Buy	119,553 +55,648	+87%	+$256K	﹤0.01%	3009
2025 Q4	$228K	Buy	+63,905	New	+$203K	﹤0.01%	3588
2023 Q3	–	Sell	-9	Closed	-$34	–	2463
2023 Q2	$34	Sell	9 -36,673	-100%	-$137K	﹤0.01%	2085
2023 Q1	$123K	Buy	+36,682	New	+$149K	﹤0.01%	1591
2021 Q4	–	Sell	-332,200	Closed	-$11.6M	–	1084
2021 Q3	$11.6M	Buy	+332,200	New	+$9.21M	0.05%	449

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Steven Cohen's AVIR Position: Q2 2026 in Review

Steven Cohen sold out of Atea Pharmaceuticals (AVIR) in Q2 2026, closing a stake of 119,553 shares — an estimated $643K sold.

Steven Cohen first reported a position in AVIR in Q3 2021 and held it in 5 quarters. The position peaked at $11.6M in Q3 2021. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

Steven Cohen reported no remaining Atea Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Steven Cohen sold 119,553 Atea Pharmaceuticals shares in Q2 2026, an estimated $643K.
Steven Cohen first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 5 quarters.
Steven Cohen's Atea Pharmaceuticals position peaked at $11.6M in Q3 2021.
124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.